22.418 articles found

Different levodopa actions on the extracellular dopamine pools in the rat striatum.

Rodríguez M, Morales I, González-Mora JL, Gómez I, Sabaté M, Dopico JG, Rodríguez-Oroz MC, Obeso JA.

Synapse · 2007-02-01

DOI: 10.1002/syn.20342PMID: 17117421

Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice.

Richter F, Hamann M, Richter A.

J Neurosci Res · 2007-02-01

DOI: 10.1002/jnr.21159PMID: 17171705

Carbidopa/levodopa-responsive myoclonus.

Fitzgerald DB, Drago V, Sutherland D, Heilman KM.

Mov Disord · 2007-02-01

DOI: 10.1002/mds.21286PMID: 17216651

Exercise improves efficacy of levodopa in patients with Parkinson's disease.

Muhlack S, Welnic J, Woitalla D, Müller T.

Mov Disord · 2007-02-01

DOI: 10.1002/mds.21346PMID: 17226855

Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.

Pal PK, Sathyaprabha TN, Tuhina P, Thennarasu K.

Mov Disord · 2007-02-01

DOI: 10.1002/mds.21330PMID: 17230476

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.

Arbouw ME, van Vugt JP, Egberts TC, Guchelaar HJ.

Pharmacogenomics · 2007-02-01

DOI: 10.2217/14622416.8.2.159PMID: 17286539

Neural stem cell therapy for neuropsychiatric disorders.

Valenzuela M, Sidhu K, Dean S, Sachdev P.

Acta Neuropsychiatr · 2007-02-01

DOI: 10.1111/j.1601-5215.2007.00176.xPMID: 26952794

Methods for the treatment of synucleinopathies

LANSBURY PETER T, LIU ZHIHUA.

· 2007-01-26

Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa.

Lyons KE, Davis JT, Pahwa R.

Stereotact Funct Neurosurg · 2007-01-26

DOI: 10.1159/000099076PMID: 17259749

Advances in the treatment of Parkinson's disease.

Singh N, Pillay V, Choonara YE.

Prog Neurobiol · 2007-01-25

DOI: 10.1016/j.pneurobio.2006.11.009PMID: 17258379

Therapeutic RNA interference for neurodegenerative diseases: From promise to progress.

Gonzalez-Alegre P.

Pharmacol Ther · 2007-01-25

DOI: 10.1016/j.pharmthera.2007.01.003PMID: 17316816

USE OF A POLYPEPTIDE THAT COMPRISES THE C-TERMINAL DOMAIN OF THE HEAVY CHAIN OF TETANUS TOXIN IN THE TREATMENT OF PARKINSONISM

AGUILERA AVILA JOSE.

· 2007-01-19